No Data
Optimistic Buy Rating for Artelo Biosciences Based on Promising Developments in Cancer Anorexia Treatment
Artelo Biosciences Price Target Maintained With a $6.00/Share by D. Boral Capital
Artelo Biosciences Is Maintained at Buy by D. Boral Capital
Analysts Offer Insights on Healthcare Companies: Artelo Biosciences (ARTL) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Artelo Biosciences Presents Phase 1 Data On ART27.13 For Cancer-Related Anorexia At International Conference, Highlighting Good Tolerability And Weight Stabilization Or Reversal In Two-Thirds Of Participants; Phase 2 Enrollment Ongoing In CAReS Trial
Artelo Biosciences Announces Presentation of Phase 1 Data With ART27.13 in Cancer-Related Anorexia
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}